Literature DB >> 10403538

Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.

R W Brueggemeier1, A L Quinn, M L Parrett, F S Joarder, R E Harris, F M Robertson.   

Abstract

Aromatase, the enzyme system catalyzing estrogen biosynthesis, is found in stromal tissue in the breast. The increased expression of the aromatase CYP19 gene in breast cancer tissues was recently associated with a promoter region regulated through cAMP-mediated pathways. PGE2, derived from cyclooxygenase, increases intracellular cAMP levels and stimulates estrogen biosynthesis. This association suggest that local production of PGE2 via cyclooxgenase isozymes may influence estrogen biosynthesis. The present study represents the first to examine the levels of mRNA expression of CYP19, COX-1, and COX-2 genes in human breast cancer specimens and normal breast tissue samples using semi-quantitative RT-PCR methods. Positive correlations were observed between CYP19 and COX-2 and the greater extent of breast cancer cellularity. Linear regression analysis using a bivariate model shows a strong linear association between CYP19 expression and the sum of COX-1 and COX-2 expression. This significant relationship between the aromatase and cyclooxygenase enzyme systems suggests that autocrine and paracrine mechanisms may be involved in hormone-dependent breast cancer development via growth stimulation from local estrogen biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403538     DOI: 10.1016/s0304-3835(99)00050-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  48 in total

Review 1.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  No effect of aspirin on mammographic density in a randomized controlled clinical trial.

Authors:  Anne McTiernan; C Y Wang; Bess Sorensen; Liren Xiao; Diana S M Buist; Erin J Aiello Bowles; Emily White; Mary Anne Rossing; John Potter; Nicole Urban
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

3.  Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

Authors:  Maryam B Lustberg; Stephen P Povoski; Weiqiang Zhao; Rebecca M Ziegler; Yasuro Sugimoto; Amy S Ruppert; Amy M Lehman; Donna R Shiels; Ewa Mrozek; Bhuvaneswari Ramaswamy; Rachel M Layman; Robert W Brueggemeier; Charles L Shapiro
Journal:  Clin Breast Cancer       Date:  2011-05-19       Impact factor: 3.225

Review 4.  The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer.

Authors:  Aruna V Krishnan; Srilatha Swami; David Feldman
Journal:  Steroids       Date:  2012-07-16       Impact factor: 2.668

5.  Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Authors:  Kathrin Strasser-Weippl; Michaela J Higgins; Judith-Anne W Chapman; James N Ingle; George W Sledge; George T Budd; Matthew J Ellis; Kathleen I Pritchard; Mark J Clemons; Tanja Badovinac-Crnjevic; Lei Han; Karen A Gelmon; Manuela Rabaglio; Catherine Elliott; Lois E Shepherd; Paul E Goss
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

6.  Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study.

Authors:  Christopher G Slatore; David H Au; Alyson J Littman; Jessie A Satia; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-17       Impact factor: 4.254

7.  Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.

Authors:  Aruna V Krishnan; Srilatha Swami; Lihong Peng; Jining Wang; Jacqueline Moreno; David Feldman
Journal:  Endocrinology       Date:  2009-11-11       Impact factor: 4.736

Review 8.  [Clinical pharmacology of the selective COX-2 inhibitors].

Authors:  M Burian; G Geisslinger
Journal:  Orthopade       Date:  2003-12       Impact factor: 1.087

9.  Aromatase is phosphorylated in situ at serine-118.

Authors:  Todd W Miller; Incheol Shin; Norio Kagawa; Dean B Evans; Michael R Waterman; Carlos L Arteaga
Journal:  J Steroid Biochem Mol Biol       Date:  2008-09-04       Impact factor: 4.292

10.  Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue.

Authors:  M P Charalambous; T Lightfoot; V Speirs; K Horgan; N J Gooderham
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.